A spirulina-bound iron supplement (Monurelle Ferro Naturale) delivered to 12 iron-replete women over three consecutive days produced a mean 94.7% rise in serum iron at peak absorption (5 hours post-dose, Day 1) and a 72.0% rise by Day 3, with only one brief adverse event — a single vomiting episode — across the entire trial. The formulation pairs iron-enriched Spirulina platensis with inactivated yeast in an open-label, single-centre pharmacokinetic design.
Conventional ferrous sulfate supplements are notorious for causing nausea, constipation, and cramping, often driving patient non-adherence and treatment failure in iron-deficiency anemia — a condition affecting roughly 1.2 billion people globally. Binding iron to spirulina's protein matrix may blunt the reactive-oxygen-species generation in the gut lumen that underlies these side effects, an approach consistent with earlier in vitro and animal data on food-matrix iron delivery. The near-doubling of circulating iron within five hours is clinically meaningful if confirmed in iron-deficient populations, where absorption dynamics differ substantially from healthy controls.
However, the limitations here are profound: just 12 participants, no placebo or comparator arm, no iron-deficient subjects, no long-term efficacy data on hemoglobin or ferritin repletion, and no blinding. As a preprint posted on medRxiv and not yet peer-reviewed, these results could change materially upon independent scrutiny. Consider this intriguing proof-of-concept, not a practice-changing finding.
